
    
      The investigators designed a single center, open-label, prospective study that routinely
      administered low-dose IL-2 therapy to monitor the improvement of clinical and laboratory
      parameters to explore its efficacy and to observe changes in immune cell subsets and
      cytokines.For all patients,rhIL-2(500,000 unit per square meter) infusions seven
      days;recurrent patients were applied again for 7 days;patients who were diagnosed HSPN were
      treated on a routine basis for 7 consecutive days, and then once every two week for 3months.
    
  